Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sorafenib combined with CCR4 antagonist for restraining cancer growth and transfer

An antagonist and antagonism technology, applied in the field of biomedicine, can solve the problems of tumor growth and metastasis that have not yet been seen

Active Publication Date: 2017-02-22
INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] So far, there have been no reports on the combination of sorafenib and CCR4 antagonists for the treatment of liver cancer, kidney cancer, non-small cell lung cancer, melanoma, thyroid cancer, breast cancer, prostate cancer and other tumor growth and metastasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sorafenib combined with CCR4 antagonist for restraining cancer growth and transfer
  • Application of sorafenib combined with CCR4 antagonist for restraining cancer growth and transfer
  • Application of sorafenib combined with CCR4 antagonist for restraining cancer growth and transfer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Compound

[0032] 1. Sorafenib API was purchased from Yaodu Company.

[0033] 2. The small molecular compound c-021 was purchased from Tocris Company (product number: 3581, purity > 99%), and the molecular formula of the compound is C 27 h 41 N 5 o 2 2HCl, the structure is as follows:

[0034]

[0035] 3. The small molecular compound ST45177901 was purchased from Timtec Company (article number: MFCD04147999, purity > 99%), and the molecular formula of the compound is C 26 h 16 ClN 3 o 4 S 3 , with the following structure:

[0036]

Embodiment 2

[0037] Example 2: Detection of changes in chemokines and cytokines in liver cancer cell lines treated with Sorafenib

[0038] Real-time fluorescence quantitative PCR was used to detect the changes in the secretion levels of chemokines and cytokines after stimulation of liver cancer cell lines with different concentrations of sorafenib, and to screen out the highly secreted factors induced by sorafenib.

[0039] 1. Cells

[0040] Mouse hepatoma cell line Hepa1-6 cells were purchased from ATCC Cell Bank (Product No.: CRL-1830).

[0041] 2. Drugs

[0042] Treat Hepa1-6 cells with different concentrations of sorafenib for 48h:

[0043] Experimental group 1: 4 μM sorafenib was added to the cell culture medium and cultured for 48 hours;

[0044] Experimental group 2: 2 μM sorafenib was added to the cell culture medium and cultured for 48 hours;

[0045] Control group: add an equal volume of DMSO and culture for 48 hours.

[0046] 3. Experimental equipment

[0047] Instrument n...

Embodiment 3

[0051] Example 3: Animal experiment of Sorafenib combined with CCR4 antagonist for the treatment of liver cancer growth and metastasis

[0052] The mouse subcutaneous tumor-bearing model is a model for routine observation of tumor growth and metastasis, so it is used to verify the effect of Sorafenib combined with CCR4 antagonists on the growth and metastasis of liver cancer.

[0053] 1. Animals

[0054] C57BL / 6 mice (all male, weighing 20-24 g, 6 mice per group / cage) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and were raised in an SPF animal room. A total of 6 groups were divided into experiments.

[0055] 2. Cells

[0056] The mouse liver cancer cell line Hepa1-6 cells were purchased from the ATCC cell bank (product number: CRL-1830), and each mouse was inoculated with 3*10 6 cells, and experimental mice were obtained.

[0057] 3. Drugs

[0058] Group the experimental mice into groups:

[0059] Experimental group 1: intragastric a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of sorafenib combined with a CCR4 antagonist for restraining cancer growth and transfer, belongs to the technical field of biological medicine and specifically relates to the application of a sorafenib drug and a CCR4 antagonist, especially, combination of C-021 and ST45177901, for restraining the growth and transfer of tumors, such as, liver cancer, kidney cancer, lung cancer, breast cancer, melanin cancer, thyroid cancer and prostate cancer. The compound combined treatment provided by the invention has excellent clinical application prospects in restraining the growth and transfer of the tumors, especially liver cancer, kidney cancer, lung cancer, breast cancer, melanin cancer, thyroid cancer and prostate cancer.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of sorafenib combined with CCR4 antagonists in inhibiting cancer growth and metastasis. Background technique [0002] Sorafenib (sorafenib) is an oral multikinase inhibitor, which can effectively inhibit tumor cell proliferation and angiogenesis, and has a significant therapeutic effect on liver cancer and kidney cancer. It has also been reported in the treatment research of breast cancer, prostate cancer and other cancers. [0003] Liver cancer is one of the most common clinical malignant tumors, with the characteristics of high malignancy, rapid progression, and poor prognosis, which seriously threatens human health and life safety. China is the country with the highest incidence and the highest number of deaths from liver cancer in the world, accounting for about 55% of the world's liver cancer patients. In recent years, the incidence of liver cancer in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/517A61K31/433A61K31/44A61P35/00
Inventor 杨鹏远高雅楠杜成志
Owner INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com